Tumor‐associated macrophages and risk of recurrence in stage <scp>III</scp> colorectal cancer-Reference-Cited by-同舟云学术

Tumor‐associated macrophages and risk of recurrence in stage III colorectal cancer

Published:2022-03-23 Issue:4 Volume:8 Page:307-312
ISSN:2056-4538
Container-title:The Journal of Pathology: Clinical Research
language:en
Short-container-title:The Journal of Pathology CR

Author:

Cavalleri Tommaso¹,Greco Luana¹^ORCID,Rubbino Federica¹,Hamada Tsuyoshi²,Quaranta Maria³,Grizzi Fabio⁴⁵,Sauta Elisabetta⁶,Craviotto Vincenzo⁷,Bossi Paola⁸,Vetrano Stefania³⁴,Rimassa Lorenza⁴⁹,Torri Valter¹⁰,Bellazzi Riccardo⁶,Mantovani Alberto⁴⁵¹¹,Ogino Shuji¹²¹³¹⁴¹⁵^ORCID,Malesci Alberto⁴⁷,Laghi Luigi¹¹⁶

Affiliation:

1. Laboratory of Molecular Gastroenterology IRCCS Humanitas Research Hospital Milan Italy

2. Department of Gastroenterology Graduate School of Medicine, The University of Tokyo Tokyo Japan

3. IBD Center – Laboratory of Gastrointestinal Immunopathology IRCCS Humanitas Research Hospital Milan Italy

4. Department of Biomedical Sciences Humanitas University Milan Italy

5. Department of Immunology and Inflammation IRCCS Humanitas Research Hospital Milan Italy

6. Department of Electrical, Computer and Biomedical Engineering University of Pavia Pavia Italy

7. Department of Gastroenterology IRCCS Humanitas Research Hospital Milan Italy

8. Department of Pathology IRCCS Humanitas Research Hospital Milan Italy

9. Medical Oncology and Hematology Unit, Humanitas Cancer Center IRCCS Humanitas Research Hospital Milan Italy

10. Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS Milan Italy

11. The William Harvey Research Institute Queen Mary University of London London UK

12. Program in Molecular Pathological Epidemiology, Department of Pathology Brigham & Women's Hospital and Harvard Medical School Boston MA USA

13. Department of Epidemiology Harvard T.H. Chan School of Public Health Boston MA USA

14. Associate Member Broad Institute of MIT and Harvard Cambridge MA USA

15. Cancer Immunology and Cancer Epidemiology Programs Dana‐Farber Harvard Cancer Center Boston MA USA

16. Department of Medicine and Surgery University of Parma Parma Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

NIH Clinical Center

Publisher

Wiley

Subject

Pathology and Forensic Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cjp2.267

Reference16 articles.

1. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

2. Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives

3. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

4. Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

5. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrophages and tertiary lymphoid structures as indicators of prognosis and therapeutic response in cancer patients;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

2. Converting “cold” to “hot”: epigenetics strategies to improve immune therapy effect by regulating tumor‐associated immune suppressive cells;Cancer Communications;2024-05-07

3. An Epic Advancement in Targeting Macrophages for Cancer Therapy Approach;Current Drug Delivery;2024-04-08

4. Tumor Microenvironment Heterogeneity, Potential Therapeutic Avenues, and Emerging Therapies;Current Cancer Drug Targets;2024-03

5. Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation;Chemical Society Reviews;2024